HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has upgraded Context Therapeutics (NASDAQ:CNTX) from Neutral to Buy and set a price target of $5.
November 01, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Context Therapeutics has been upgraded from Neutral to Buy by HC Wainwright & Co. with a new price target of $5.
The upgrade from Neutral to Buy by a reputable analyst at HC Wainwright & Co. is a positive signal for Context Therapeutics. The new price target of $5 also indicates an expected increase in the stock's value. This could lead to a short-term positive impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100